GlassScriptPhysician profile
Michael A Picariello
NPI 1487642906
$3,658.68
in general payments reported to CMS, 2019-2025
34 companies · $759 in 2025
The $759 reported for 2025 was more than what 76% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $498 · 2021: $331 · 2022: $428 · 2023: $591 · 2024: $624 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.77 |
| Education | $155.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $722.90 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $627.08 | 2019-2025 | Dupixent, Libtayo |
| Glaxosmithkline, LLC. | $408.19 | 2019-2025 | Nucala |
| Acclarent, INC | $323.63 | 2019-2023 | Trudi Nav Cable |
| Stryker Corporation | $198.95 | 2019-2025 | Xpress Loprofile |
| Aerin Medical INC. | $173.54 | 2019-2025 | |
| Harmony Biosciences LLC | $166.52 | 2023-2025 | Wakix |
| Optinose US, INC. | $142.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $121.27 | 2019-2024 | |
| Genentech USA, INC. | $120.18 | 2019-2024 | Xolair |
| Kaleo, INC. | $66.61 | 2019-2023 | Auvi-Q |
| Intersect Ent, INC. | $55.29 | 2020-2022 | |
| Alk-Abello, INC | $44.05 | 2019-2025 | Alternaria Tenuis, Pre-Pen, Standardized Mite D. Farinae |
| Phathom Pharmaceuticals, INC. | $35.15 | 2025 | Voquezna |
| Smith+Nephew, INC. | $34.45 | 2023 | Rapid Rhino, Tula |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $32.90 | 2024 | Sunosi |
| Ars Pharmaceuticals Operations, INC. | $30.94 | 2025 | Neffy |
| Arbor Pharmaceuticals, INC. | $30.24 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $29.10 | 2023 | Iovera, Exparel |
| Takeda Pharmaceuticals U.S.A., INC. | $24.60 | 2020 | |
| Octapharma USA, INC. | $23.92 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.14 | 2020 | |
| Integra Lifesciences Corporation | $23.10 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Medline Industries LP | $22.99 | 2024 | |
| Merck Sharp & Dohme LLC | $21.01 | 2023 | |
| Pfizer INC. | $20.82 | 2023 | |
| Resmed Corp | $20.42 | 2024 | |
| Sanofi US Services INC. | $20.42 | 2024 | |
| Inspire Medical Systems, INC. | $19.80 | 2023 | Inspire |
| Lilly USA, LLC | $19.19 | 2024 | Zepbound |
| Medtronic USA, INC. | $16.36 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $15.44 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $12.76 | 2021 | |
| Cook Medical LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Picariello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.